Viking Therapeutics Reports Q2 2026 Financial Results

What Happened

• On July 29, 2026, Viking Therapeutics, Inc. (VKTX) issued a press release reporting its financial results for the quarter ended June 30, 2026 and providing a corporate update. The press release is furnished as Exhibit 99.1 to the Current Report on Form 8‑K and is incorporated by reference. The Form 8‑K was signed by President and CEO Brian Lian, Ph.D.

Key Details

• Date of press release: July 29, 2026 (covers quarter ended June 30, 2026).
• Filing: Form 8‑K filed under Item 2.02 (Results of Operations and Financial Condition); Exhibit 99.1 contains the full press release.
• Signature: Report signed by Brian Lian, Ph.D., President and Chief Executive Officer, on July 29, 2026.
• The Form 8‑K furnishes the press release; detailed financial figures and corporate update are in Exhibit 99.1 (not reproduced in full in the 8‑K text).

Why It Matters

• The filing signals that Viking has released its latest quarterly results and a corporate update—information investors use to assess revenue, expenses, cash runway, and program progress. Because the 8‑K furnishes (and incorporates) the press release, investors should read Exhibit 99.1 or the company’s investor relations release for the specific financials and operational details before making investment decisions.